Opthea Limited (ASX:OPT)
0.6000
0.00 (0.00%)
Mar 14, 2025, 4:10 PM AEST
Opthea Revenue
Opthea had revenue of $149.00K USD in the half year ending December 30, 2024, a decrease of -24.39%. This brings the company's revenue in the last twelve months to $208.86K, down -46.47% year-over-year. In the fiscal year ending June 30, 2024, Opthea had annual revenue of $261.86K, down -32.03%.
Revenue (ttm)
$208.86K
Revenue Growth
-46.47%
P/S Ratio
2,198.24
Revenue / Employee
$6.33K
Employees
33
Market Cap
738.77M AUD
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 261.86K | -123.42K | -32.03% |
Jun 30, 2023 | 385.28K | 186.27K | 93.60% |
Jun 30, 2022 | 199.01K | 103.44K | 108.24% |
Jun 30, 2021 | 95.56K | -5.13K | -5.09% |
Jun 30, 2020 | 100.69K | -136.12K | -57.48% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Mesoblast | 9.16M |
Opthea News
- 16 days ago - ASX 200 LIVE: Trump tariffs; sharemarket drops 1pc on Wednesday, iron ore slumps; US equities fall on escalating US-China trade war - The Australian Financial Review
- 23 days ago - Phil King’s Regal writes Opthea to zero and backs off risky bets - The Australian Financial Review
- 24 days ago - Opthea (OPT) Halts Key Trials Following Disappointing Results - GuruFocus
- 25 days ago - Opthea in active talks with funders after second trial fails - The Australian Financial Review
- 25 days ago - Opthea Announces Decision to Discontinue Wet AMD Trials - GlobeNewsWire
- 4 weeks ago - The clinical trial result from hell has biotech investors on edge - The Australian Financial Review
- 4 weeks ago - Pengana freezes fund redemptions as it braces for big Opthea loss - The Australian Financial Review
- 4 weeks ago - ASX 200 LIVE: Donald Trump eyeing copper tariffs; February CPI below forecasts; sharemarket rises. - The Australian Financial Review